

A Clinical Trial in Small-Cell Lung Cancer (SCLC)

For patients with limited-stage SCLC who have completed chemotherapy and radiation therapy without progression.



ClinicalTrials.gov Number: NCT06117774

TarlatamabClinicalTrials.com


About This Clinical Trial

What is the DeLLphi-306 Clinical Trial?

DeLLphi-306 is a Phase 3 clinical trial for patients with limited-stage small-cell lung cancer. This means they have cancer in just one lung, or possibly one lung and nearby lymph nodes. They also must have been treated with chemotherapy and radiation at the same time. Participants will be randomly assigned to receive the investigational drug (tarlatamab) or a placebo.

What is tarlatamab?

Tarlatamab is a type of immunotherapy called a bispecific T-cell engager, or BiTE® molecule, that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.



Tarlatamab moves throughout the body finding T-cells and cancer cells

Tarlatamab attaches to a T-cell and a cancer cell and brings them close together

Tarlatamab enables the T-cell to attack the cancer cell, which stimulates the T-cell to multiply and attack other cancer cells

What is a placebo?

A placebo is an inactive substance that does not include any medicine. Clinical trials often use placebos when they are testing new drugs and there is no standard treatment available. Participants in DeLLphi-306 will have stable small-cell lung cancer after completing their initial treatment. Standard of care is usually imaging without additional treatment.

You may be able to join DeLLphi-306 if you are at least 18 years old and:

- ✓ SCLC in only one lung, or one lung and nearby lymph nodes.
- ✓ Diagnosed with SCLC by examining a tumor sample under a microscope.
- ✓ Received a platinum-based chemotherapy and etoposide at the same time as radiotherapy.
- ✓ Ongoing response or no progression after chemoradiation.

Participants must also meet additional eligibility criteria. Clinical trials have strict rules. This protects people who join the trial and ensures that the results of the trial can be trusted. Your doctor can help you decide if this trial is right for you by reviewing the rules and your health history.

For Physicians

For more information about eligibility criteria, please speak to your healthcare team or call Amgen Medical Information at 1-800-772-6436 (1-800-77-AMGEN)



ClinicalTrials.gov Number:

NCT06117774